Європейський Союз - фінська - EMA (European Medicines Agency)

biogen netherlands b.v. - dimetyylifumaraatti - multippeliskleroosi - immunosuppressantit - tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Європейський Союз - фінська - EMA (European Medicines Agency)

biogen netherlands b.v. - peginterferoni beeta-1a - multippeliskleroosi - immunostimulantit, - relapsoivan remasteroitavan multippeliskleroosin hoito aikuispotilailla.

Європейський Союз - фінська - EMA (European Medicines Agency)

biogen netherlands b.v. - natalitsumabin - multippeliskleroosi - selektiiviset immunosuppressantit - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 ja 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Європейський Союз - фінська - EMA (European Medicines Agency)

biogen netherlands b.v. - nusinersen natriumia - lihassärky, spinaali - muut hermoston huumeet - spinraza on tarkoitettu 5q spinal lihasatrofian hoitoon.

Європейський Союз - фінська - EMA (European Medicines Agency)

biogen netherlands b.v. - diroximel fumarate (biib098) - multippeliskleroosi, relapsoiva-remittoiva - immunosuppressantit - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).

Європейський Союз - фінська - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibitsumabi - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - silmätautien - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Фінляндія - фінська - Fimea (Suomen lääkevirasto)

biovail technologies (ireland) ltd - diltiazemi hydrochloridum - depotkapseli, kova - 120 mg - diltiatseemi

Фінляндія - фінська - Fimea (Suomen lääkevirasto)

biovail technologies (ireland) ltd - diltiazemi hydrochloridum - depotkapseli, kova - 180 mg - diltiatseemi

Фінляндія - фінська - Fimea (Suomen lääkevirasto)

biovail technologies (ireland) ltd - diltiazemi hydrochloridum - depotkapseli, kova - 240 mg - diltiatseemi

Фінляндія - фінська - Fimea (Suomen lääkevirasto)

biovail technologies (ireland) ltd - diltiazemi hydrochloridum - depotkapseli, kova - 300 mg - diltiatseemi